These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 33857784)

  • 1. Risk adapted therapeutic strategy in newly diagnosed acute myeloid leukemia: Refining the outcomes of ELN 2017 intermediate-risk patients.
    Mohty R; Massoud R; Chakhachiro Z; Mahfouz R; Nassif S; El-Cheikh J; Bazarbachi A; Abou Dalle I
    Leuk Res; 2021 Jun; 105():106568. PubMed ID: 33857784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.
    Boddu PC; Kadia TM; Garcia-Manero G; Cortes J; Alfayez M; Borthakur G; Konopleva M; Jabbour EJ; Daver NG; DiNardo CD; Naqvi K; Yilmaz M; Short NJ; Pierce S; Kantarjian HM; Ravandi F
    Cancer; 2019 Apr; 125(7):1091-1100. PubMed ID: 30521114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.
    Oran B; Jimenez AM; De Lima M; Popat UR; Bassett R; Andersson B; Borthakur G; Bashir Q; Chen J; Ciurea SO; Jabbour E; Cortes J; Kebriaei P; Khouri IF; Qazilbash MH; Ravandi F; Rondon G; Lu X; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1405-1412. PubMed ID: 25840338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
    Borlenghi E; Cattaneo C; Cerqui E; Archetti S; Bertoli D; Bellotti D; Gramegna D; Soverini G; Oberti M; Schieppati F; Pagani C; Passi A; Sciumé M; Farina M; Carbone C; Crippa C; Dalceggio D; Tucci A; Rossi G
    Hematol Oncol; 2020 Dec; 38(5):754-762. PubMed ID: 32950042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
    Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Outcomes of adult patients with
    Ren X; Zhao T; Wang J; Zhu HH; Jiang H; Jia JS; Yang SM; Jiang B; Wang DB; Huang XJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jan; 39(1):15-21. PubMed ID: 29551027
    [No Abstract]   [Full Text] [Related]  

  • 7. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients.
    Jackson K; Kennedy G; Mollee P; Marlton P; Morris K
    Asia Pac J Clin Oncol; 2014 Sep; 10(3):246-54. PubMed ID: 24673966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial.
    Hyakuna N; Hashii Y; Ishida H; Umeda K; Takahashi Y; Nagasawa M; Yabe H; Nakazawa Y; Koh K; Goto H; Fujisaki H; Matsumoto K; Kakuda H; Yano M; Tawa A; Tomizawa D; Taga T; Adachi S; Kato K
    Pediatr Blood Cancer; 2019 Oct; 66(10):e27875. PubMed ID: 31309713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation.
    Choi YW; Jeong SH; Ahn MS; Lee HW; Kang SY; Choi JH; Park JS
    J Korean Med Sci; 2015 Oct; 30(10):1416-22. PubMed ID: 26425037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.
    Sasaki K; Kantarjian HM; Kadia T; Patel K; Loghavi S; Garcia-Manero G; Jabbour EJ; DiNardo C; Pemmaraju N; Daver N; Dalle IA; Short N; Yilmaz M; Bose P; Naqvi K; Pierce S; Yalniz F; Cortes JE; Ravandi F
    Cancer; 2019 Nov; 125(21):3755-3766. PubMed ID: 31310323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response.
    Begna KH; Kittur J; Gangat N; Alkhateeb H; Patnaik MS; Al-Kali A; Elliott MA; Hogan WJ; Litzow MR; Pardanani A; Hanson CA; Ketterling RP; Tefferi A
    Blood Cancer J; 2022 Jan; 12(1):7. PubMed ID: 35039473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
    Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
    Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
    Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of the efficacy of IA and HAD induction regimens in the treatment of patients with newly diagnosed acute myeloid leukemia: a single-center study].
    Zhang CX; Qiu SW; Gong BF; Gong XY; Li Y; Liu YT; Fang QY; Zhang GJ; Liu KQ; Zhou CL; Wei SN; Lin D; Liu BC; Wang Y; Mi YC; Wei H; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):383-387. PubMed ID: 35680595
    [No Abstract]   [Full Text] [Related]  

  • 17. Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation.
    Parovichnikova EN; Loukianova IA; Troitskaya VV; Drokov MY; Lobaova TI; Kuzmina LA; Sokolov AN; Kokhno AV; Fidarova ZT; Baskhaeva GA; Gavrilina OA; Vasilyeva VA; Obukhova TN; Kuznetsova SA; Sudarikov AB; Dvirnik VN; Galtseva IV; Davidiva JO; Kulikov SM; Savchenko VG
    Ter Arkh; 2018 Aug; 90(7):14-22. PubMed ID: 30701918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome.
    Bouchacourt B; Hospital MA; Zemmour C; Rey J; d'Incan E; Charbonnier A; Mohty B; Saillard C; Bonnet S; Collignon A; Gelsi-Boyer V; Mozziconacci MJ; Blaise D; Vey N
    Ann Hematol; 2020 Apr; 99(4):773-780. PubMed ID: 32088745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
    Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
    J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of an Additional Chromosome on the Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Acute Myeloid Leukemia in Adults.
    Min GJ; Kim HJ; Yoon JH; Kwak DH; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1621-1628. PubMed ID: 29698793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.